These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 176030)

  • 21. Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.
    de Jager R; Brugarolas A; Hansen H; Cavalli F; Ryssel H; Siegenthaler P; Clarysse A; Renard J; Kenis Y; Alberto P
    Eur J Cancer (1965); 1979 Jul; 15(7):971-4. PubMed ID: 385328
    [No Abstract]   [Full Text] [Related]  

  • 22. [Advances made in the chemistry of alkylating agents and treatment of cancer].
    Machoń Z
    Postepy Hig Med Dosw; 1975; 29(4):443-72. PubMed ID: 1178586
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical experiences with dibromodulcitol (NSC-104800) in solid tumors.
    Phillips RW; Brook J
    Cancer Chemother Rep; 1971 Dec; 55(5):567-73. PubMed ID: 4946081
    [No Abstract]   [Full Text] [Related]  

  • 24. [New antineoplastic chemotherapeutic drugs--alkylating agents].
    Rezábek K
    Cas Lek Cesk; 1972 Nov; 111(45):1060. PubMed ID: 5084853
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II trial of dianhydrogalactitol in the treatment of children with refractory childhood malignancies: a report from the Children's Cancer Study Group.
    Finklestein JZ; Shore N; Krivit W; Hammond D; Higgins G
    Cancer Treat Rep; 1985 Nov; 69(11):1331-3. PubMed ID: 4092198
    [No Abstract]   [Full Text] [Related]  

  • 26. Alkylating agent resistance.
    Clapper ML; Tew KD
    Cancer Treat Res; 1989; 48():125-50. PubMed ID: 2577134
    [No Abstract]   [Full Text] [Related]  

  • 27. Combined treatment of anaplastic astrocytoma (grade 3-4) with diacetyl-dianhydro-galactitol (DADAG).
    Afra D; Kerpel-Fronius S; Szinai I; Kocsis B; Eckhardt S
    J Neurooncol; 1990 Feb; 8(1):85-91. PubMed ID: 2319295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alkylating agents.
    Connors TA
    Cancer Chemother Biol Response Modif; 1991; 12():27-42. PubMed ID: 1931447
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti cancer drugs (cancer chemotherapy).
    Roy SL
    Indian Med J; 1965 Oct; 59(10):229-32. PubMed ID: 5847430
    [No Abstract]   [Full Text] [Related]  

  • 30. [Chemotherapy of malignant tumor growth. III. Substances with an alkylating effect].
    Zikán V; Semonský M; Semonská S
    Cesk Farm; 1979 Mar; 28(2):62-81. PubMed ID: 116774
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase I evaluation of dianhydrogalactitol (NSC-132313).
    Haas CD; Stephens RL; Hollister M; Hoogstraten B
    Cancer Treat Rep; 1976 May; 60(5):611-4. PubMed ID: 991150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The need for additional alkylating agents and antimetabolites.
    Heidelberger C
    Cancer Res; 1969 Dec; 29(12):2435-42. PubMed ID: 4905240
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cytostatic drugs. 1: Platinum compounds, alkylating and intercalating cytostatic drugs].
    Bauch HJ
    Med Monatsschr Pharm; 1989 Jan; 12(1):8-20. PubMed ID: 2643766
    [No Abstract]   [Full Text] [Related]  

  • 34. [Cancer chemotherapy (author's transl)].
    Ramirez G
    Rev Med Chil; 1978 Oct; 106(10):797-800. PubMed ID: 741124
    [No Abstract]   [Full Text] [Related]  

  • 35. 1,2:5,6-Dianhydrogalactitol in advanced breast cancer.
    Hoogstraten B; O'Bryan R; Jones S
    Cancer Treat Rep; 1978 May; 62(5):841-2. PubMed ID: 657167
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of meturedepa (NSC-51325) in 233 patients with advanced cancer. Eastern Clinical Drug Evaluation Program.
    Moore GE; Bross ID; Ausman R; Nadler S; Jones R; Slack N; Rimm AA
    Cancer Chemother Rep; 1968 Oct; 52(6):667-73. PubMed ID: 4895430
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical evaluation of a new alkylating agent, azetepa, in one hundred and twenty-five cases of malignant tumors.
    Choy DS; Arandia J; Rosenbaum I
    Int J Cancer; 1967 Mar; 2(2):189-93. PubMed ID: 6039768
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemoimmunotherapy of cancer.
    Soloway AH; Wright JE; Subramanyam V; Gozzo JJ
    J Med Chem; 1977 Nov; 20(11):1357-62. PubMed ID: 335066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adverse events and those managements of alkylating agents].
    Matsuoka H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():139-42. PubMed ID: 25831738
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I clinical trials of WR-2721 with alkylating agent chemotherapy.
    Glick JH; Glover DJ; Weiler C; Blumberg A; Nelson D; Yuhas JM; Kligerman M
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):575-80. PubMed ID: 6286556
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.